The Latest Cardiac and Vascular News
PARIS and NEW YORK, June 27, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, informs its shareholders that […]
PARIS and NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of a new scientific article in the […]
PARIS and NEW YORK, April 26, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, announces the publication of the full results from its Phase […]
PARIS and NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure has released its annual results for the 2018 fiscal […]
PARIS and NEW YORK, March 20, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company announces positive results from preclinical reproductive toxicity studies conducted in rats and rabbits with firibastat, a first-in-class cerebral aminopeptidase A inhibitor (BAPAI, Brain Aminopeptidase A Inhibitor). The results of these preclinical […]
PARIS, Jan. 31, 2019 (GLOBE NEWSWIRE) — Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specializing in the development of a new drug class that directly targets the brain to treat resistant hypertension and heart failure, today presents its 2019 corporate action plan. The end of 2018 was marked […]
